Announcements Trials
Browse Landscape

Phase

Phase 2 74Phase 1 18Phase 1/2 13Phase 3 7Phase EARLY_PHASE1 4Phase 4 3Phase 2/3 2Phase NA 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3Carcinoma, Ovarian Epithelial 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 31Bupivacaine 31Vincristine 27Propofol 25Methotrexate 25Cisplatin 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Bevacizumab 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Idarubicin 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × OTHER × niraparib × Clear all
NCT06412120 2026-04-23

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

University of Miami

Phase 4 Recruiting
70 enrolled
Gynecologic

Ovarian Neoplasms

NCT03752216 2024-12-13

NiQoLe

ARCAGY/ GINECO GROUP

Phase 4 Completed
141 enrolled
Gynecologic

Ovarian Neoplasms

NCT05187208 2022-01-26

POLO

Seoul National University Hospital

Phase 4 Unknown
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡